iRadimed (NASDAQ:IRMD – Get Free Report) announced its quarterly earnings results on Friday. The medical equipment provider reported $0.55 EPS for the quarter, meeting the consensus estimate of $0.55, FiscalAI reports. iRadimed had a return on equity of 23.45% and a net margin of 26.70%. The business had revenue of $24.20 million for the quarter, compared to analyst estimates of $23.47 million.
Here are the key takeaways from iRadimed’s conference call:
- Record third-quarter results included revenue of $24.2 million, up 14% year over year and 18% sequentially, while GAAP EPS rose to $0.51 from $0.43 a year ago.
- The 3870 MR IV pump launch is gaining traction, with more than 300 systems shipped in Q3, record pump and monitor bookings, and a growing backlog. Management estimates an opportunity of more than 10,000 replacement channels, with the new pump carrying an approximately 23%-25% higher ASP than the older model.
- The company reduced its 2026 revenue outlook to $91.7 million-$93.2 million from $91 million-$96 million and lowered its GAAP EPS range to $1.90-$1.94 from $1.90-$2.05, citing the need to moderate production ramping to protect quality.
- Manufacturing efficiencies lifted gross margin to 76% sequentially, and management expects further improvement in Q4 and potentially a return to 77%-78% or higher in 2027. Management also projected double-digit, potentially upper-teens, revenue growth in 2027 and ended the quarter with $63.3 million in cash while declaring a $0.20 quarterly dividend.
iRadimed Stock Performance
Shares of NASDAQ IRMD traded down $9.06 during mid-day trading on Friday, hitting $76.68. 218,003 shares of the stock were exchanged, compared to its average volume of 105,373. iRadimed has a twelve month low of $76.35 and a twelve month high of $107.90. The stock’s fifty day simple moving average is $85.66 and its two-hundred day simple moving average is $92.69. The company has a market cap of $980.74 million, a P/E ratio of 42.84 and a beta of 0.91.
Key iRadimed News
Here are the key news stories impacting iRadimed this week:
- Positive Sentiment: Record revenue and year-over-year growth: Third-quarter revenue reached $24.2 million, up 14% from the prior-year period and 18% sequentially. Revenue also exceeded the FactSet consensus estimate of $23.5 million. iRadimed Third Quarter 2026 Financial Results
- Positive Sentiment: Improved profitability: GAAP diluted EPS was $0.51, while non-GAAP diluted EPS was $0.55, up from $0.41 and $0.47, respectively, in the second quarter. Non-GAAP EPS matched analysts’ consensus estimate, while the company maintained a 26.7% net margin and 23.45% return on equity. IRadimed Q3 Earnings and Outlook
- Positive Sentiment: Potential production acceleration: Management expects fourth-quarter revenue of $25 million to $26.5 million and is targeting more than 50% sequential growth in output for its MRidium 3870 infusion pump, supporting a potential path toward a $100 million annual revenue run rate. iRadimed Q4 Revenue Outlook
Insider Activity at iRadimed
In related news, Director Monty K. Allen sold 1,419 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total transaction of $122,615.79. Following the sale, the director directly owned 19,581 shares in the company, valued at $1,691,994.21. This represents a 6.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 34.60% of the stock is owned by insiders.
Analysts Set New Price Targets
Several research firms have issued reports on IRMD. Wall Street Zen lowered iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings upgraded shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 16th. Finally, Needham & Company LLC started coverage on shares of iRadimed in a research note on Tuesday, September 22nd. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $120.00.
Read Our Latest Analysis on iRadimed
About iRadimed
iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.
Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.
Read More
- Five stocks we like better than iRadimed
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
